What are the downsides of Ipamorelin?

The biggest downside is how little is known. Ipamorelin’s only sizable trial, in 114 patients after bowel surgery, missed its primary endpoint, and development stopped. It was well tolerated in that study, but long-term safety in people has never been characterized, and it isn’t FDA approved for any use. Other human data cover only short-term growth hormone release.

Mechanism-based effects are also worth tracking in any study. Activating the ghrelin receptor can raise hunger, which changes food intake and body weight in animals, and headache is among the effects most often reported. The World Anti-Doping Agency prohibits growth hormone secretagogues, including ipamorelin. Peptide quality is another risk, so check the lot report in our COA library. Shop Ipamorelin Peptide.